GLP1R and Parkinson disease: Furthermore, the incidence of PD was significantly reduced in diabetic patients using certain diabetes drug classes, such as glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1-degrading enzyme dipeptidyl peptidase 4 inhibitors (150).